Former Chief Development Officer · Evelo Biosciences, Inc. (EVLO)

Jonathan Zung

A named executive officer of Evelo Biosciences in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,107,563

Salary $432,000Stock awards $0

FY2021: $4,559,337

2nd of 3 named executive officers at Evelo Biosciences by FY2022 total.

3 named officers on file for Evelo Biosciences, FY2022

Jonathan Zung’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Evelo Biosciences’s whole pay program stands against its peers

  • Evelo Biosciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on EVLO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A).

Free

Get Jonathan Zung’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jonathan Zung compensation by year

Evelo Biosciences Summary Compensation Table · all 2 fiscal years held
In US dollars, as Evelo Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$415,000$432,000
Bonus$110,000$0
Stock awards$166,500$0
Option awards$3,679,560$627,348
Non-equity incentive$141,100$0
Pension and deferred compensation$0$0
All other$47,177$48,215
Total$4,559,337$1,107,563

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Evelo Biosciences, Inc. DEF 14A filed April 28, 2023, accession 0001193125-23-127000, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Evelo Biosciences, Inc. filed document, accession 0001193125-23-127000. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

$4.6M
$1.1M
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,000$16,100—
Option156,250—$16.65
Option115,000—$2.24
Option88,652—$5.05

Per the Outstanding Equity Awards at Fiscal Year-End table in Evelo Biosciences, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Evelo Biosciences’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Balkrishan GillChief Executive Officer$1,721,635
Jonathan Zung · this pageFormer Chief Development Officer$1,107,563
Marella ThorellChief Financial Officer$1,029,097

The full Evelo Biosciences compensation record

free company brief

This page is one person within Evelo Biosciences's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Evelo Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jonathan Zung's compensation dossier · One-time report. No refunds.